Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 2Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 18OTHER 12OTHER_GOV 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasm Female 1Breast Cancer Recurrent 1

Interventions

Radiotherapy 138Cyclophosphamide 108Cisplatin 103Doxorubicin 99Vincristine 76Filgrastim 60Etoposide 58Paclitaxel 56Carboplatin 53Fluorouracil 51Methotrexate 49Dexamethasone 49Cytarabine 43Prednisone 42Leucovorin 40Granulocyte Colony-Stimulating Factor 34Docetaxel 34Radiation 31Specimen Handling 30Tamoxifen 27Daunorubicin 27Magnetic Resonance Spectroscopy 26Calcium Dobesilate 26Ifosfamide 25Mercaptopurine 24Gemcitabine 24Platinum 22Goserelin 221,2-diaminocyclohexaneplatinum II citrate 22Chemotherapy, Adjuvant 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × NETWORK × palbociclib × Clear all
NCT03425838 2026-05-20

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Borstkanker Onderzoek Groep

Phase 3 Active not recruiting
1,050 enrolled
Breast

Breast Neoplasm Female

NCT03820830 2026-04-09

POLAR

ETOP IBCSG Partners Foundation

Phase 3 Active not recruiting
405 enrolled
Breast

Breast Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡